News | July 30, 2009

Study Refutes Better Renal Safety of Iodixanol Compared to Low-Osmolar Contrast Media

July 30, 2009 – A new study comparing nephrotoxicity of the iso-osmolar contrast medium iodixanol to low-osmolar contrast media (LOCM) found iodixanol shows no reduction in contrast-induced acute kidney injury (CI-AKI) compared to some agents, which may prompt the ACC and AHA to change their current guidelines.

The research shows the more expensive iodixanol (Visipaque, made by GE Healthcare) is better than some of the less expensive LOCM, but is equal to others. The study found a reduction in CI-AKI when iodixanol was compared with ioxaglate and iohexol, but no difference when compared with iopromide (Ultravist, Bayer Healthcare) or ioversol (Optiray, Mallinckrodt).

Earlier studies showed iodixanol offered better kidney protection that LOCM, which led the ACC/AHA to set guidelines recommending iso-osmolar contrast media in patients with chronic kidney disease undergoing angiography. Iodixanol is the only FDA-cleared iso-osmolar agent. However, in addition to the current report, some recent larger randomized trials comparing iodixanol with different types of LOCM have shown no reduction in kidney injury. Experts say new data may prompt the ACC and AHA to review its guidelines.

The study, published in the July issue of JACC Cardiac Interventions, sought to compare the nephrotoxicity of the iso-osmolar contrast medium, iodixanol, to (LOCM). Researchers from the University of Michigan, VA Ann Arbor Healthcare System, and the University of Miami, Fla., looked at 2,763 patients from 16 trials between 1980 to November 2008, which compared the incidence of CI-AKI with either iodixanol or LOCM. Random-effects models were used to calculate summary risk ratios for CI-AKI, need for hemodialysis, and death.

The data shows no significant difference in the incidence of CI-AKI in the iodixanol group than in the LOCM group overall. There was no significant difference in the rates of post-procedure hemodialysis or death. The relative renal safety of LOCM compared with iodixanol may vary based on the specific type of LOCM.

The study authors said a prior meta-analysis suggested that iodixanol was associated with less CI-AKI than LOCM, but this study was limited by ascertainment bias and did not include the most recent randomized controlled trials.

For more information: http://interventions.onlinejacc.org

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init